News | March 16, 2009

Invatec Receives CE-mark for Second Drug-Eluting Balloon Platform


March 16, 2009 – Invatec today announced CE-certification of a new coronary balloon, the IN.PACT Falcon paclitaxel-eluting PTCA balloon catheter, which is one of the first drug-eluting balloons designed specifically to treat atherosclerosis in the coronary arteries.

IN.PACT Falcon features FreePac, a proprietary, natural coating that frees and separates paclitaxel molecules and facilitates their absorption into the wall of the artery. The FreePac coating was developed in close collaboration with the researchers who pioneered drug-eluting balloon therapy, Ulrich Speck, Ph.D., department of radiology at Charite Mitte, Berlin, and Bruno Scheller, M.D., University Hospital Department of Internal Medicine, Homburg/Saar.

“The drug-eluting balloon concept has already shown its potential to reduce re-intervention rates for patients with coronary atherosclerosis in clinical trials in a selected patient population,” said Prof. Scheller and Prof. Speck “Therefore the launch of efficacious matrix coatings on modern coronary balloon catheters by renowned medical device manufacturers is a major milestone in the development of appropriate ways to treat coronary atherosclerosis. It is also an essential precondition to incorporate clinical practice as the driving force for further improvements.”

“Combining world-class PTCA balloon catheter technology with local drug administration is a fascinating new concept for the treatment of certain coronary lesions such as in-stent restenosis (ISR), bifurcations, small vessel disease (SVD) and potentially other lesions where conventional balloons, stents and even drug eluting stents may not be ideal. A drug eluting balloon such as the IN.PACT Falcon that elutes a known and effective drug such as paclitaxel holds much promise as an effective treatment option for patients.”

In addition to IN.PACT Falcon paclitaxel-eluting balloon, Invatec recently launched IN.PACT Amphirion, its first drug-eluting balloon designed specifically for the treatment of atherosclerosis in arteries located below the knee. The launch of IN.PACT Falcon is the company’s second drug eluting balloon platform.

For more information: www.invatec.com


Related Content

News | Balloon Catheter

April 4, 2024 — The U.S. Food and Drug Administration (FDA) announced that Medos International Sàrl is recalling ...

Home April 04, 2024
Home
News | Balloon Catheter

January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for ...

Home January 18, 2024
Home
News | Balloon Catheter
Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional ...
Home February 25, 2022
Home
News | Balloon Catheter

February 15, 2022 – CERENOVUS, an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices ...

Home February 15, 2022
Home
News | Balloon Catheter

May 20, 2021 — Boston Scientific Corporation announced it has initiated the AGENT IDE trial for the Agent Drug-Coated ...

Home May 20, 2021
Home
Feature | Balloon Catheter | By Dave Fornell, Editor

The first devices developed for interventional cardiology were percutaneous transluminal coronary angioplasty (PTCA) ...

Home March 16, 2021
Home
Feature | Balloon Catheter

February 17, 2021 — The U.S. Food and Drug Administration (FDA) has cleared Shockwave Medical's Intravascular ...

Home February 17, 2021
Home
News | Balloon Catheter

June 4, 2020 — Transit Scientific announced the U.S. Food and Drug Administration (FDA) cleared the XO Score ...

Home June 04, 2020
Home
News | Balloon Catheter

February 24, 2020 — Abbott has voluntarily recalled specific lots of two types of its coronary angioplasty catheters — ...

Home February 24, 2020
Home
News | Balloon Catheter

July 15, 2019 — Edwards LifeSciences is recalling the IntraClude Intra-Aortic Occlusion Device due to a risk of balloon ...

Home July 15, 2019
Home
Subscribe Now